Pacitti Group Inc. decreased its position in Merck & Co., Inc. (NYSE:MRK) by 23.4% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 637 shares of the company’s stock after selling 195 shares during the period. Pacitti Group Inc.’s holdings in Merck & Co., Inc. were worth $49,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in MRK. Sowa Financial Group Inc. purchased a new stake in shares of Merck & Co., Inc. in the 4th quarter worth about $27,000. Total Clarity Wealth Management Inc. acquired a new position in Merck & Co., Inc. during the fourth quarter worth about $27,000. Stephenson National Bank & Trust purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at about $28,000. Pacifica Partners Inc. purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at about $35,000. Finally, Lion Street Advisors LLC purchased a new position in shares of Merck & Co., Inc. during the 1st quarter worth approximately $35,000. Institutional investors and hedge funds own 74.33% of the company’s stock.
In related news, Director Wendell P. Weeks sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $76.02, for a total value of $380,100.00. Following the transaction, the director now owns 5,100 shares in the company, valued at $387,702. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.28% of the stock is currently owned by corporate insiders.
MRK has been the topic of a number of analyst reports. Mizuho reiterated a “buy” rating on shares of Merck & Co., Inc. in a report on Wednesday, February 5th. ValuEngine raised Merck & Co., Inc. from a “sell” rating to a “hold” rating in a research note on Saturday, February 29th. Royal Bank of Canada cut their target price on shares of Merck & Co., Inc. from $92.00 to $89.00 and set a “sector perform” rating for the company in a research note on Wednesday, April 1st. UBS Group decreased their price target on shares of Merck & Co., Inc. from $96.00 to $92.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Finally, Barclays cut their price objective on shares of Merck & Co., Inc. from $93.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, April 29th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $94.21.
Shares of MRK stock traded down $1.06 on Monday, reaching $79.66. 144,295 shares of the stock were exchanged, compared to its average volume of 10,026,432. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 0.82. The stock has a market cap of $203.75 billion, a P/E ratio of 20.44, a price-to-earnings-growth ratio of 2.24 and a beta of 0.50. The firm has a 50 day moving average of $79.53 and a two-hundred day moving average of $83.11. Merck & Co., Inc. has a 1-year low of $65.25 and a 1-year high of $92.64.
Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.34 by $0.16. The firm had revenue of $12.06 billion during the quarter, compared to the consensus estimate of $11.46 billion. Merck & Co., Inc. had a return on equity of 52.46% and a net margin of 21.10%. The firm’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.22 earnings per share. On average, equities research analysts predict that Merck & Co., Inc. will post 5.31 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 7th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.61 per share. This represents a $2.44 dividend on an annualized basis and a dividend yield of 3.06%. The ex-dividend date is Friday, June 12th. Merck & Co., Inc.’s payout ratio is currently 47.01%.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.